Empagliflozin Tablets are an oral selective sodium‑glucose cotransporter 2 (SGLT2) inhibitor for the management of type 2 diabetes mellitus.
It works by blocking the reabsorption of glucose in the kidney, thereby increasing urinary glucose excretion and reducing blood glucose levels independently of insulin secretion.
Indications
Treatment of type 2 diabetes mellitus in adults to improve glycemic control, alone or in combination with other antidiabetic medicines.
Reduction of the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Renal protection in patients with chronic kidney disease and type 2 diabetes.
Key Features
Insulin‑independent glucose lowering
Once‑daily oral administration
Associated with moderate weight loss and blood pressure reduction
Proven cardiovascular and renal protective effects
Low risk of hypoglycemia
Good safety and tolerability profile
Manufactured under strict GMP conditions
Complies with USP, EP and other international pharmacopoeial standards
Complete registration dossiers available for global markets
Storage
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
Important Note
Contraindicated in patients with hypersensitivity to empagliflozin or any excipient.
Use with caution in patients with renal impairment, hypotension, or risk of ketoacidosis.
For prescription use only.
